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Objective:  
Angiogenesis is a critical component in 
the development of metastatic disease 
in patients with epithelial ovarian 
carcinoma.  Mutations of the p53 gene 
are frequent in epithelial ovarian cancer 
and have been associated with an 
increase in angiogenesis.  We 
hypothesize changes in tumor 
vascularity are associated with 
mutations in the p53 gene in patients 
with metastatic epithelial ovarian 
carcinoma.      
Methods:  
Searching our divisional database, we 
identified patients diagnosed with stage 
IIIC or IV epithelial ovarian carcinoma 
who had undergone primary surgery 
and had tissue available for analysis 
from both primary and metastatic 
disease sites. Microscopic slides were 
cut from paraffin-embedded tissue and 
stained for the vascular endothelial 
marker CD31.  Microvessel density 
(MVD) counts were determined by 
averaging three high power fields within 
the tumor section with the greatest 
concentration of tumor and were 
expressed as vessels/high power field 
(HPF).  The average MVD counts for 
metastatic sites were determined under 
microscopic examination and compared 
to MVD counts from primary ovarian 
cancer sites.  Clinical and pathologic 
factors included in the analysis were 
histology, grade, and p53 mutational 
status.  Absolute differences in MVD 
counts between primary and distant 
tissue sites of > 7 vessels/HPF or ≤ 7 
vessels/HPF dichomatized the tumors 
into two groups. Results were analyzed 
by chi-square testing. 
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Results:  
A total of 46 patients with primary 
epithelial ovarian cancer were included 
in our analysis.  Serous histology was 
associated with absolute differences (>7 
vessels/HPF) between MVD counts in 
primary vs. metastatic tumor sites 
(p=0.07), as was an identified p53 
mutation (p=0.03).  There was no 
association between absolute 
differences in MVD counts and grade 
(p=0.30) or stage (p=0.98).  In our 
limited cohort there was no difference in 
survival between those with absolute 
MVD >7 vessels/HPF vs. ≤ 7 
vessels/HPF 
 
 
 
 
 
 
 
 
 
 
Conclusions: 
Mutations of the p53 tumor suppressor 
gene are associated with large 
differences (>7 vessels/HPF) in MVD 
counts between primary and metastatic 
tumor sites in patients with epithelial 
ovarian cancer.  These data are 
consistent with models demonstrating 
p53 mutation functions directly to 
influence angiogenesis. This information 
supports continued therapy and 
research involving angiogenesis 
inhibitors in patients with ovarian 
cancer, especially in the setting of 
increased differences in MVD between 
primary and metastatic sites. 
